title: Caelyx: treatment for relapsing ovarian cancer.
abstract: Although there have been significant improvements in the first-line treatment of ovarian cancer, the options for patients who relapse have been limited. Caelyx is a new treatment using long-circulating liposomes to target delivery of doxorubicin to the tumour. This article reviews the treatment of ovarian cancer and looks at the place of Caelyx as a new second-line treatment option.
authors.affiliation: Royal Marsden Hospital, London SW3 6JJ.
authors.forename: S R
authors.initials: SR
authors.lastname: Johnston
authors.forename: S
authors.initials: S
authors.lastname: Kaye
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008081:Liposomes; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin